8 results on '"Mahendru, Diksha"'
Search Results
2. Abstract 16560: Home Blood Pressure Monitoring Among Hypertensive Patients and Their Caregivers in a North Indian Population
- Author
-
Singhania, Anusha, Singla, Ankur, Kalsi, Harsimran, Mahendru, Diksha, Singh, Samneet, Goyal, Ishaan, Ghosh, Hiyanoor, Uppal, Aditya, Dhand, Nishma, Bansal, Namita, Batta, Akash, Dhanda, Aaina, Mittal, Ankush, SHARMA, SARIT, Sharma, Meenakshi, Shivashankar, Roopa, singh, kavita, Wander, Gurpreet S, and Mohan, Bishav
- Published
- 2023
- Full Text
- View/download PDF
3. PSMA-Targeted Therapy: Advancements in Detection and Treatment Modalities with Dr. Scott T. Tagawa.
- Author
-
Cortiana, Viviana, Gambill, Jade, Chorya, Harshal, Mahendru, Diksha, Amin, Fabiha, Park, Chandler H., and Leyfman, Yan
- Subjects
PROSTATE tumors treatment ,RADIOISOTOPE therapy ,DOSE-response relationship (Radiation) ,RADIOTHERAPY ,EARLY detection of cancer ,IMMUNOTHERAPY ,PROSTATE tumors ,POSITRON emission tomography ,DECISION making in clinical medicine ,RADIOISOTOPE brachytherapy ,RADIOISOTOPES ,PROSTATE-specific membrane antigen ,COMBINED modality therapy ,INDIVIDUALIZED medicine - Abstract
Simple Summary: Prostate cancer presents significant challenges due to its high incidence and prevalence, as it is the most common non-skin cancer in men. The timely detection of prostate cancer and its metastasis is crucial for patient outcomes. Prostate-specific membrane antigen (PSMA) emerges as a promising biomarker for its early detection, due to its specificity and membrane localization on tumor cells. Utilizing PSMA-targeting particles in conjunction with positron emission tomography (PET) scans enhances the accuracy of tumor detection compared to PET alone. This advancement has led to innovative treatment modalities such as Prostate-specific membrane antigen-targeted radionuclide therapies (PSMA-TRTs), which have shown promise in reducing or eliminating tumors, as evidenced by declines in prostate-specific antigen (PSA) levels post treatment. However, PSMA-TRT carries both benefits and adverse effects, with the long-term ones as yet unknown. The short-term adverse effects include fatigue, nausea, pain flares, and potential radiation exposure to others. Further research is needed to explore PSMA-TRT's long-term efficacy and potential applications beyond prostate cancer. Prostate cancer is one of the most challenging malignancies due to its high incidence and prevalence, as it is the most frequently diagnosed non-skin cancer in men. The timely identification of prostate cancer and its metastasis is paramount for ensuring favorable outcomes for patients. Prostate-specific membrane antigen (PSMA) emerges as a promising biomarker for its detection, due to its specificity. This makes it an ideal target for the early identification of a metastatic phenotype. Situated on the membrane of tumor cells, PSMA facilitates the attachment of PSMA-targeting particles, enabling their detection through positron emission tomography (PET) scans with relative ease. Utilizing these imaging agents in conjunction with PET scans enhances the accuracy of prostate cancer tumor detection compared to PET scans alone. The advancement in prostate cancer imaging has paved the way for innovative treatment modalities. Prostate-specific membrane antigen-targeted radionuclide therapies (PSMA-TRT) exploit PSMA imaging agents to target identified prostate cancer malignancies with precise radiation, thereby reducing or eliminating the tumor mass. PSMA-TRT exhibits significant promise in prostate cancer therapy, evident from the notable declines in prostate-specific antigen (PSA) levels post treatment. However, PSMA-TRT carries both beneficial and adverse effects. While it represents a substantial leap forward in tumor cell imaging, PSMA-based antigens, being larger particles than ligands, offer prolonged imaging capabilities. Yet, the long-term effects of PSMA-TRT remain unknown, with the short-term adverse ones including fatigue, nausea, pain flares, and potential radiation exposure to others. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Reviewing the Landscape of Cancer Survivorship: Insights from Dr. Lidia Schapira's Programs and Beyond.
- Author
-
Cortiana, Viviana, Abbas, Rabab Hunaid, Nadar, Soumiya, Mahendru, Diksha, Gambill, Jade, Menon, Gayathri Pramil, Park, Chandler H., and Leyfman, Yan
- Subjects
TUMOR prevention ,HEALTH literacy ,HOLISTIC medicine ,HUMAN services programs ,MENTAL health ,PRESUMPTIONS (Law) ,CANCER patient medical care ,EARLY detection of cancer ,PHYSICIANS' attitudes ,INFORMATION resources ,PATIENT-centered care ,PROFESSIONS ,QUALITY of life ,HEALTH promotion ,CANCER patient psychology ,ONCOLOGISTS ,INDIVIDUALIZED medicine ,WELL-being - Abstract
Simple Summary: This review begins by exploring the escalating global population of cancer survivors, drawing inspiration from Dr. Lidia Schapira's Keynote Conference on Survivorship 1.0 and Survivorship 2.0 Programs. It presents and discusses the transformed and constantly evolving landscape of cancer care, emphasizing patient-centric strategies within Cancer Survivorship Programs, including connection, support, and education. While spotlighting cancer recurrence surveillance, concerns arise regarding potential oversights in addressing the enduring mental and physical health impacts. The study further navigates mental health challenges faced by survivors providing strategies to mitigate them, insights into promising research areas, such as Precision Medicine's role in de-escalating oncology therapies, as well as advocating for early cancer awareness and referrals to supportive services. Dr. Schapira's insights also extend to examining online resources, emphasizing their role in educating healthcare practitioners and future generations in cancer care. Additionally, the paper aims to identify knowledge gaps in cancer care and envision future developments toward accurate, holistic care, improving survivor quality of life, and enhancing mental and physical well-being. The constantly escalating population of cancer survivors worldwide has prompted a focused exploration of their unique needs and experiences within the context of healthcare medicine. This review initiates its analysis inspired by Dr. Lidia Schapira's insightful keynote conference on the Survivorship 1.0 and Survivorship 2.0 Programs, shedding light on their implementation challenges and setting the stage for a comprehensive analysis of cancer survivorship initiatives. Within the transformed landscape of cancer care, patient-centric strategies embedded in cancer survivorship programs comprising vital elements such as connection, support, and education are presented. While placing cancer recurrence surveillance at the forefront, the review underlines concern regarding the potential oversight of the enduring impact on mental and physical health. Dr. Schapira's insights further extend into the exploration of mental health challenges faced by survivors, promoting an examination of diverse strategies to address these concerns. Furthermore, the discussion continues toward promising areas of research, notably Precision Medicine's role in de-escalating cancer therapies, and advocates for measures such as early cancer awareness and timely referrals to supportive services. Highlighting the significance of education, the role of online resources in enhancing the knowledge of healthcare practitioners and future generations in cancer care is then explored. The paper concludes by presenting some of the most prominent global current survivorship programs, identifying critical knowledge gaps in cancer care and projecting future developments aimed at delivering accurate and holistic care, improving the quality of life for survivors, and enhancing both mental and physical well-being. Drawing upon the insights from Dr. Schapira, this review lays the groundwork for a nuanced exploration of cancer survivorship and its multifaceted implications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Cholangiocarcinoma Insights: Established Foundations and Cutting-Edge Innovations from Dr. James Cleary's Pioneering Research.
- Author
-
Cortiana, Viviana, Chorya, Harshal, Joshi, Muskan, Kannan, Shreevikaa, Mahendru, Diksha, Vallabhaneni, Harshitha, Coloma, Helena S., Leyfman, Yan, and Park, Chandler H.
- Subjects
ASSOCIATIONS, institutions, etc. ,FIBROBLAST growth factors ,CELL differentiation ,BILE duct tumors ,GENETIC mutation ,CHOLANGIOCARCINOMA ,CELL receptors ,INDIVIDUALIZED medicine ,GENOMICS ,MEDICAL research ,DIFFUSION of innovations ,PHENOTYPES - Abstract
Simple Summary: Biliary tract malignancies, including cholangiocarcinoma (CCA) and gallbladder neoplasms, present intricate challenges in diagnosis and treatment. This comprehensive overview highlights the diversity of CCA subtypes, their genetic underpinnings, and the pivotal role of etiological factors. Despite diagnostic complexities, advancements in genomic sequencing reveal promising therapeutic targets, such as FGFR2 alterations and IDH1 mutations. Dr. James Cleary's insights underscore the potential of these targets in reshaping the treatment landscape. This paper provides insights into the conventional understanding of biliary tract malignancies and emphasizes the critical need for ongoing research to optimize outcomes in this challenging cancer subtype. By elucidating diverse FGFR2 alterations and the potential of IDH1 inhibition, the aim is to pave the way for targeted therapeutic interventions. As we delve deeper into understanding the intricate complexities of biliary tract malignancies, this research seeks to drive precision medicine forward, offering hope for improved treatment strategies and outcomes in the face of this formidable cancer. This paper provides insights into the conventional understanding of biliary tract malignancies, with a specific focus on cholangiocarcinoma (CCA). We then delve into the groundbreaking ideas presented by Dr. James Cleary. CCA, originating from biliary tree cells, manifests diverse subtypes contingent upon anatomical localization and differentiation status. These variants exhibit discrete genetic aberrations, yielding disparate clinical phenotypes and therapeutic modalities. Intrahepatic, perihilar, and distal CCAs intricately involve distinct segments of the biliary tree, further categorized as well-differentiated, moderately differentiated, or poorly differentiated adenocarcinomas based on their histological differentiation. Understanding the etiological factors contributing to CCA development assumes paramount importance. Stratifying these factors into two groups, those unrelated to fluke infestations (e.g., viral hepatitis and fatty liver conditions) and those associated with fluke infestations (e.g., chronic liver inflammation), facilitates predictive modeling. The epidemiology of CCA exhibits global variability, with Southeast Asia notably displaying higher incidences attributed primarily to liver fluke infestations. Jaundice resulting from bile duct obstruction constitutes a prevalent clinical manifestation of CCA, alongside symptoms like malaise, weight loss, and abdominal pain. Diagnostic challenges arise due to the symptomatic overlap with other biliary disorders. Employing comprehensive liver function tests and imaging modalities such as computed tomography assumes a pivotal role in ensuring accurate diagnosis and staging. However, the definitive confirmation of CCA necessitates a biopsy. Treatment modalities, predominantly encompassing surgical resection and radiation therapy, hold curative potential, although a considerable subset of patients is deemed unresectable upon exploration. Challenges intensify, particularly in cases classified as cancer of unknown origin, underscoring the imperative for early intervention. Advancements in genomic sequencing have revolutionized precision medicine in CCA. Distinct genomic markers, including fibroblast growth factor receptor 2 (FGFR2) alterations and isocitrate dehydrogenase 1 (IDH1) mutations, have emerged as promising therapeutic targets. FGFR2 alterations, encompassing mutations and rearrangements, play pivotal roles in oncogenesis, with FGFR inhibitors demonstrating promise despite identified resistance mechanisms. Similarly, IDH1 inhibitors face challenges with resistance, despite encouraging early clinical trial results, prompting exploration of novel irreversible inhibitors. Dr. James Cleary's illuminating discourse underscores the significance of diverse FGFR2 alterations and the potential of IDH1 inhibition in reshaping the treatment landscape for CCA. These findings unveil critical avenues for targeted therapeutic interventions, emphasizing the critical need for ongoing research to optimize outcomes in this challenging cancer subtype, incorporating innovative insights from Dr. Cleary. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Factors affecting adherence to pharmacotherapy in parkinson's disease
- Author
-
Aggarwal, Shivaansh, Paul, Gunchan, Paul, Birinder, Mahendru, Diksha, and Goyal, Shriya
- Subjects
Patient compliance -- Evaluation ,Parkinson's disease -- Drug therapy -- Patient outcomes ,Health - Abstract
Byline: Shivaansh. Aggarwal, Gunchan. Paul, Birinder. Paul, Diksha. Mahendru, Shriya. Goyal Background: The goal of dopaminergic replacement therapy to achieve good clinical outcome in Parkinson's disease (PD) patients largely depends [...]
- Published
- 2021
7. Blood Pressure Measurement Knowledge and Practices Among Healthcare Workers in a Tertiary Care Hospital in North India
- Author
-
Singhania, Anusha, Singla, Ankur, Mahendru, Diksha, Kalsi, Harsimran, Katyal, Jatin, Muralidharan, Ksheeraja, Malhotra, Sanvi, Farooqi, Muzammil, Saluja, Anshdeep, Batta, Akash, Singal, Gautam, Sharma, Sarit, Dhanda, Aaina, Mittal, Ankush, and Mohan, Bishav
- Published
- 2023
- Full Text
- View/download PDF
8. SLEEP DISORDERS AMONG PHYSICIANS: A SYSTEMATIC REVIEW OF PREVALENCE, IMPACT ON BURNOUT, AND PATIENT SAFETY
- Author
-
TAWFEEQ, SAWSAN, SINGH, AAKANKSHA, DILIP MEHTA, PRIYAL, MAHENDRU, DIKSHA, BANSAL, VIKAS, ARSHAD, ZARA, NAWAZ, FAISAL, and KASHYAP, RAHUL
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.